01:26 PM EDT, 07/23/2024 (MT Newswires) -- Cellectar Biosciences ( CLRB ) shares were down nearly 19% in recent Tuesday trading after the company released updated data for its investigational radiotherapy Iopofosine I 131, showing a drop in major response rate.

As of the May 31 cutoff, Iopofosine I 131 was found to have a major response rate of 56.4% in patients with Waldenstrom's macroglobulinemia, a type of blood cancer -- down from the 61% MRR the company had reported in January.

Updated data from the CLOVER WaM study also showed an overall response rate of 80%, up from the 75.6% the company reported at the start of the year.

Cellectar is developing Iopofosine I 131 for patients who no longer respond to treatment, including Bruton tyrosine kinase inhibitors.

The company said it would file a new drug application for its radiotherapy in Q4 and seek a priority review from the US Food and Drug Administration.

Price: 2.45, Change: -0.57, Percent Change: -18.87